Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome
Dec282020

Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program Updates

December 28, 2020
Dec222020

Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020

December 22, 2020
Nov62020

Proof of Concept Controlled Phase 2 Clinical Trial Data Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease Dementia Presented at CTAD 2020 Conference

November 6, 2020
Jun42020

Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s Disease

June 4, 2020
Apr232020

Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimer’s Disease

April 23, 2020
Mar312020

Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19

March 31, 2020
Mar232020

Anavex Life Sciences to Webcast 2020 Annual Meeting of Shareholders

March 23, 2020
Dec162019

Anavex Life Sciences Reports Fiscal Year 2019 Financial Results  And Provides Clinical Study Updates

December 16, 2019
Dec102019

Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019

December 10, 2019
Dec42019

Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Conference

December 4, 2019
Oct92019

Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease 

October 9, 2019
Jul172019

Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Response in Patients Treated with ANAVEX®2-73 at 2019 Alzheimer’s Association International Conference (AAIC)

July 17, 2019
123

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top